IP Library › Granted Patent US 12,708,673
Granted Patent B2
US 12,708,673 · App. 17/681,380 · Granted Aug 18, 2026

Methods and compositions related to peptides and proteins with c-terminal elements

Inventors: Erkki Ruoslahti (La Jolla, CA); Tambet Teesalu (La Jolla, CA); Kazuki Sugahara (La Jolla, CA)
Assignee: Sanford Burnham Prebys Medical Discovery Institute
A61K47/6923A61K47/62A61K47/64
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,708,673
App. No.
17/681,380
Filed
Feb 25, 2022
Granted
Aug 18, 2026
Kind
B2
Art Unit
1654
USPC
424/9.1
Abstract

Disclosed are compositions and methods useful for targeting and internalizing molecules into cells of interest and for penetration by molecules of tissues of interest. The compositions and methods are based on peptide sequences that are selectively internalized by a cell, penetrate tissue, or both. The disclosed internalization and tissue penetration is useful for delivering therapeutic and detectable agents to cells and tissues of interest.

Claims (20)

1 . A method of forming an activatable CendR element, the method comprising (a) selecting an amino acid sequence for internalization into a cell, tissue penetration, or both, wherein the amino acid sequence comprises a CendR element comprising a terminal carboxyl group, (b) causing a blocking group to be covalently coupled to the terminal carboxyl group of the CendR element, wherein a bond coupling the blocking group and the CendR element is cleavable, wherein the blocking group covalently coupled to the CendR element reduces or prevents internalization into a cell, tissue penetration, or both, wherein the activatable CendR element comprises the selected amino acid sequence and the blocking group, wherein cleavage of the activatable CendR element exposes the terminal carboxyl group of the CendR element, wherein the amino acid sequence is circular, and wherein the CendR element comprises the sequence KLAK (amino acids 11-14 of SEQ ID NO:5), KPAR (amino acids 4-7 of SEQ ID NO: 114), KPER (amino acids 4-7 of SEQ ID NO:90), KPLR (amino acids 4-7 of SEQ ID NO: 63), KPRR (amino acids 5-8 of SEQ ID NO: 126), KQAR (amino acids 4-7 of SEQ ID NO: 64), KRDR (amino acids 3-6 of SEQ ID NO:89), KRER (amino acids 4-7 of SEQ ID NO:91), KTAR (amino acids 3-6 of SEQ ID NO:56), RGDK (amino acids 2-5 of SEQ ID NO:4), RPAK (amino acids 4-7 of SEQ ID NO: 112), or RTPK (amino acids 4-7 of SEQ ID NO:84).

2 . The method of claim 1 , wherein the activatable CendR element is a protease-activatable CendR element.

3 . The method of claim 1 , wherein the amino acid sequence is selected for internalization into a cell.

4 . The method of claim 1 , wherein the amino acid sequence is selected for tissue penetration.

5 . The method of claim 1 , wherein the amino acid sequence is selected for internalization into a cell and tissue penetration.

6 . The method of claim 1 , wherein the blocking group covalently coupled to the CendR element reduces or prevents internalization into a cell.

7 . The method of claim 1 , wherein the blocking group covalently coupled to the CendR element reduces or prevents tissue penetration.

8 . The method of claim 1 , wherein the blocking group covalently coupled to the CendR element reduces or prevents internalization into a cell and tissue penetration.

9 . An activatable CendR element made by a method comprising (a) selecting an amino acid sequence for internalization into a cell, tissue penetration, or both, wherein the amino acid sequence comprises a CendR element comprising a terminal carboxyl group, (b) causing a blocking group to be covalently coupled to the to the terminal carboxyl group of the CendR element, wherein a bond coupling the blocking group and the CendR element is cleavable, wherein the blocking group covalently coupled to the CendR element reduces or prevents internalization into a cell, tissue penetration, or both, wherein the activatable CendR element comprises the selected amino acid sequence and the blocking group, wherein cleavage of the activatable CendR element exposes the terminal carboxyl group of the CendR element, and wherein the amino acid sequence is circular, and wherein the CendR element comprises the sequence KLAK (amino acids 11-14 of SEQ ID NO:5), KPAR (amino acids 4-7 of SEQ ID NO: 114), KPER (amino acids 4-7 of SEQ ID NO:90), KPLR (amino acids 4-7 of SEQ ID NO: 63), KPRR (amino acids 5-8 of SEQ ID NO: 126), KQAR (amino acids 4-7 of SEQ ID NO: 64), KRDR (amino acids 3-6 of SEQ ID NO:89), KRER (amino acids 4-7 of SEQ ID NO:91), KTAR (amino acids 3-6 of SEQ ID NO:56), RGDK (amino acids 2-5 of SEQ ID NO:4), RPAK (amino acids 4-7 of SEQ ID NO:112), or RTPK (amino acids 4-7 of SEQ ID NO:84).

10 . The CendR element of claim 9 , wherein the activatable CendR element is a protease-activatable CendR element.

11 . The CendR element of claim 9 , wherein the method further comprises, prior to step (b), selecting the bond coupling the blocking group and the terminal carboxyl group to be cleavable by a protease present in proximity to the cell.

12 . The CendR element of claim 9 , wherein the blocking group is coupled to the C-terminal amino acid of the CendR element.

13 . The CendR element of claim 9 , wherein the blocking group is coupled to an amino acid of the CendR element other than the C-terminal amino acid of the CendR element.

14 . The CendR element of claim 9 , wherein a cargo composition is covalently coupled or non-covalently associated with a protein or peptide comprising the selected amino acid sequence, wherein the cargo composition is coupled or associated with the protein or peptide on the N terminal side of the CendR element.

15 . The CendR element of claim 9 , wherein the amino acid sequence is selected for internalization into a cell.

16 . The CendR element of claim 9 , wherein the amino acid sequence is selected for tissue penetration.

17 . The CendR element of claim 9 , wherein the amino acid sequence is selected for internalization into a cell and tissue penetration.

18 . The CendR element of claim 9 , wherein the blocking group covalently coupled to the CendR element reduces or prevents internalization into a cell.

19 . The CendR element of claim 9 , wherein the blocking group covalently coupled to the CendR element reduces or prevents tissue penetration.

20 . The CendR element of claim 9 , wherein the blocking group covalently coupled to the CendR element reduces or prevents internalization into a cell and tissue penetration.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 27, 2024
From: RUOSLAHTI, ERKKI; TEESALU, TAMBET; SUGAHARA, KAZUKI
To: BURNHAM INSTITUTE FOR MEDICAL RESEARCH
Reel/Frame 069420/0075 →
CHANGE OF NAME Recorded Nov 27, 2024
From: BURNHAM INSTITUTE FOR MEDICAL RESEARCH
To: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
Reel/Frame 069458/0174 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2022
From: RUOSLAHTI, ERKKI; TEESALU, TAMBET; SUGAHARA, KAZUKI
To: SANFORD MEDICAL PREBYS MEDICAL DISCOVERY INSTITUTE
Reel/Frame 059466/0931 →
Continuity (3)
Continuation 12390061 · Feb 20, 2009
Provisional Application 61030409 · Feb 21, 2008
Related Publication 20230173097A1 · Jun 8, 2023
References Cited (314)
US 5262176A · Palmacci · 1993 [cited by applicant]
US 5662885A · Pollak · 1997 [cited by applicant]
US 6177542B1 · Ruoslahti · 2001 [cited by applicant]
US 6530944B2 · West · 2003 [cited by applicant]
US 6576239B1 · Ruoslahti · 2003 [cited by applicant]
US 6967238B2 · Blaschuk · 2005 [cited by applicant]
US 7034109B2 · Bonny · 2006 [cited by applicant]
US 7063847B1 · Sanderson · 2006 [cited by applicant]
US 7544767B2 · Ruoslahti · 2009 [cited by applicant]
US 10500246B2 · Ruoslahti et al. · 2019 [cited by applicant]
US 20010002150A1 · Frigo · 2001 [cited by applicant]
US 20020055174A1 · Rittner · 2002 [cited by applicant]
US 20020068272A1 · Larocca · 2002 [cited by applicant]
US 20020132990A1 · Huston · 2002 [cited by applicant]
US 20020193295A1 · Calenoff · 2002 [cited by applicant]
US 20030003100A1 · Levy · 2003 [cited by applicant]
US 20030077289A1 · Wang · 2003 [cited by applicant]
US 20030082143A1 · Larocca · 2003 [cited by applicant]
US 20030082176A1 · Lebowitz · 2003 [cited by applicant]
US 20030083261A1 · Yu · 2003 [cited by applicant]
US 20030125283A1 · Gatenby · 2003 [cited by applicant]
US 20030148263A1 · Larocca · 2003 [cited by applicant]
US 20030166601A1 · Woodle · 2003 [cited by applicant]
US 20040005309A1 · Lebowitz · 2004 [cited by applicant]
US 20040219169A1 · Bermudes · 2004 [cited by applicant]
US 20050038239A1 · Catchpole · 2005 [cited by applicant]
US 20050054563A1 · Desnoyer · 2005 [cited by applicant]
US 20050071088A1 · Landfield · 2005 [cited by applicant]
US 20050085417A1 · Wickstrom · 2005 [cited by applicant]
US 20050147993A1 · Khan · 2005 [cited by applicant]
US 20050233356A1 · Jones · 2005 [cited by applicant]
US 20050260756A1 · Troy · 2005 [cited by applicant]
US 20050281805A1 · Lebowitz · 2005 [cited by applicant]
US 20060014712A1 · Neuman · 2006 [cited by applicant]
US 20060051315A1 · Scaria · 2006 [cited by applicant]
US 20060070133A1 · Dean · 2006 [cited by applicant]
US 20060100134A1 · Guo · 2006 [cited by applicant]
US 20060147922A1 · Watts · 2006 [cited by applicant]
US 20060147997A1 · Ramakrishnan · 2006 [cited by applicant]
US 20060153775A1 · Von Wronski · 2006 [cited by applicant]
US 20060154340A1 · Louie · 2006 [cited by applicant]
US 20060160743A1 · Zhang · 2006 [cited by applicant]
US 20060172941A1 · Rastelli · 2006 [cited by applicant]
US 20060233807A1 · Svanborg · 2006 [cited by applicant]
US 20060239968A1 · Arap · 2006 [cited by applicant]
US 20060242725A1 · Strong · 2006 [cited by applicant]
US 20060257942A1 · Waldo · 2006 [cited by applicant]
US 20070041904A1 · Jiang · 2007 [cited by applicant]
US 20070111251A1 · Rosania · 2007 [cited by applicant]
US 20070111270A1 · Zhang · 2007 [cited by applicant]
US 20070157328A1 · Ramrakha · 2007 [cited by applicant]
US 20070212332A1 · Baylink · 2007 [cited by applicant]
US 20070231862A1 · Diamond · 2007 [cited by applicant]
US 20070287680A1 · Cuchelkar · 2007 [cited by applicant]
US 20070292920A1 · Lin · 2007 [cited by applicant]
US 20070299043A1 · Hunter · 2007 [cited by applicant]
US 20080014143A1 · Ruoslahti · 2008 [cited by applicant]
US 20080234183A1 · Hallbrink · 2008 [cited by applicant]
US 20080305119A1 · Dewhurst · 2008 [cited by applicant]
US 20080311136A1 · Beusker · 2008 [cited by applicant]
US 20090031733A1 · Weaver · 2009 [cited by applicant]
US 20090087899A1 · McKnight · 2009 [cited by applicant]
US 20090092548A1 · Ferrara · 2009 [cited by applicant]
US 20090176660A1 · Yla-Herttuala · 2009 [cited by applicant]
US 20090176710A1 · Hadwiger · 2009 [cited by applicant]
US 20090186802A1 · Alluis · 2009 [cited by applicant]
US 20090226372A1 · Ruoslahti · 2009 [cited by applicant]
US 20090246133A1 · Ruoslahti · 2009 [cited by applicant]
US 20090257951A1 · Ruoslahti · 2009 [cited by applicant]
US 20090258926A1 · Divita · 2009 [cited by applicant]
US 20090280058A1 · Troy · 2009 [cited by applicant]
US 20090305329A1 · Szilak · 2009 [cited by applicant]
US 20090317802A1 · Bhatia · 2009 [cited by applicant]
US 20090325866A1 · Kim · 2009 [cited by applicant]
US 20100016215A1 · Moulton · 2010 [cited by applicant]
US 20100022466A1 · Raucher · 2010 [cited by applicant]
US 20100048487A1 · Uno · 2010 [cited by applicant]
US 20100061932A1 · Brock · 2010 [cited by applicant]
US 20100061942A1 · Ma · 2010 [cited by applicant]
US 20100099627A1 · Seger · 2010 [cited by applicant]
US 20100143454A1 · Mclinden · 2010 [cited by applicant]
US 20100172835A1 · Ruoslahti · 2010 [cited by applicant]
US 20100279918A1 · Langel · 2010 [cited by applicant]
US 20260048133A1 · Ruoslahti et al. · 2026 [cited by applicant]
EP 0045665 · 1982 [cited by applicant]
JP 2004512275 · 2004 [cited by applicant]
JP 2006257074 · 2006 [cited by applicant]
JP 2007511209 · 2007 [cited by applicant]
WO 1995022996 · 1995 [cited by applicant]
WO 2002018572 · 2002 [cited by applicant]
WO 0231109 · 2002 [cited by applicant]
WO WO2003106491 · 2003 [cited by examiner]
WO 03106491 · 2003 [cited by applicant]
WO 2004074432 · 2004 [cited by applicant]
WO 2005042034 · 2005 [cited by applicant]
WO 2006096207 · 2006 [cited by applicant]
WO 2007014391 · 2007 [cited by applicant]
WO 2007090194 · 2007 [cited by applicant]
WO 2007108749 · 2007 [cited by applicant]
WO 2009036092 · 2009 [cited by applicant]
WO 2009105671 · 2009 [cited by applicant]
WO 2009126349 · 2009 [cited by applicant]
WO 2010075540 · 2010 [cited by applicant]
Caveliers, et al., “Evaluation of 99mTc-RP128 as a potential inflammation imaging agent: human dosimetry and first clinical results”, [cited by applicant]
Monsky, et al., “Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor”, [cited by applicant]
Morishiita, et al., “A novel approach using functional peptides for efficient intestinal absorption of insulin”, [cited by applicant]
Ruoslahti, et al., “Vascular homing peptides with cell-penetrating properties”, [cited by applicant]
Von Wronski, et al., “Tuftsin binds neuropilin-1 through a sequence similar to that encoded by exon 8 of vascular endothelial growth factor”, [cited by applicant]
Abi-Habib, et al., “A urokinase-activated recombinant diphtheria toxin targeting the granulocyte-macrophage colony-stimulating factor receptor is selectively cytotoxic to human acute mycloid leukemia blasts”, Blood, 104… [cited by applicant]
Acevedo, et al., “Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor”, Blood , 111:2674-80 (2008). [cited by applicant]
Allam, et al., “Cholera toxin triggers apoptosis in human lung cancer cell lines”, Cancer Res., 57:2615-2618 (1997). [cited by applicant]
Almquist, et al., “Synthesis and biological activity of a ketomethylene analogue of a tripeptide inhibitor of angiotensin converting enzyme”, J. Med. Chem., 23:1392-8 (1980). [cited by applicant]
Altin and Pagler, “A one-step procedure for biotinylation and chemical cross-linking of lymphocyte surface and intracellular membrane-associated molecules”, Anal Biochem., 224: 382-9(1995). [cited by applicant]
Andreasen, “The plasminogen activation system in tumor growth, invasion, and metastasis”, Cell. Mol. Life Sci., 57:25-40 (2000). [cited by applicant]
Arap, et al., “Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model”, Science 279:377-380 (1998). [cited by applicant]
Arap, et al., “Targeting the prostate for destruction through a vascular address”, PNAS, 99:1527-1531 (2002). [cited by applicant]
Arbeit, et al., “Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice”, J Virol., 68:4358-68 (1994). [cited by applicant]
Arleth, et al., “Detailed structure of hairy mixed micelles formed by phosphatidylcholine and PEGylated phospholipids in aqueous media”, Langmuir, 21:3279-90 (2005). [cited by applicant]
Assa-Munt, et al., “Solution structures and integrin binding activities of an RGD peptide with two isomers”, Biochemistry, 40:2373-8 (2001). [cited by applicant]
Bardeesy, et al., “ Pancreatic cancer biology and genetics”, Nature Rev Cancer, 2:897-909, 2002). [cited by applicant]
Bartlett, et al., “Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging”, PNAS, 104:15549-54 (2007). [cited by applicant]
Benner, “Expanding the genetic lexicon: incorporating non-standard amino acids into proteins by ribosome-based synthesis”, TIB Tech, 12:158-63 (1994). [cited by applicant]
Berg, et al., “Physiological functions of endosomal proteolysis”, Biochem. J., 307: 313-26 (1995). [cited by applicant]
Biacchesi, et al., “Modification of the trypsin-dependent cleavage activation site of the human metapneumovirus fusion protein to be trypsin independent does not increase replication or spread in rodents or nonhuman pri… [cited by applicant]
Biology Online, accessed Dec. 23, 2016. [cited by applicant]
Blasi and Carmeliet, “uPAR: a versatile signalling orchestrator”, Nat Rev Mol Cell Biol., 3:932-43 (2002). [cited by applicant]
Brewis, et al., “Particle assembly incorporating a VP22-BH3 fusion protein, facilitating intracellular delivery, regulated release, and apoptosis”, Mol. Ther., 7:262-70 (2003). [cited by applicant]
Brooks, et al., “Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels”, Cell, 79:1157-64 (1994). [cited by applicant]
Brown and Ruoslahti, “Metadherin, a cell-surface protein in breast tumors that mediates lung metastasis”, Cancer Cell, 5:365-374 (2004). [cited by applicant]
Cahill, et al., “Site specific mutagenesis with unnatural amino acids”, TIBS, 14(10):400-3 (1989). [cited by applicant]
Chambers, et al., “Flavivirus genome organization, expression, and replication”, Annu. Rev. Microbiol., 44:649-88 (1990). [cited by applicant]
Cheresh, et al., “Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor”, J Biol Chem., 262:17703-177… [cited by applicant]
Christian, et al., “Nucleolin expressed at the cell surface is a marker of endothelial cells in tumor blood vessels”, J Cell Biol. 163:871-8 (2003). [cited by applicant]
Conese, et al., “alpha-2 Macroglobulin receptor/Ldl receptor-related protein(Lrp)-dependent internalization of the urokinase receptor”, J Cell Biol., 131:1609-22 (1995). [cited by applicant]
Curnis, et al., “Coupling tumor necrosis factor-a with av integrin ligands improves its antineoplastic activity”, Cancer Res. 64:565-571 (2004). [cited by applicant]
Debele, et al., “Specificity profiling of seven human tissue kallikreins reveals individual subsite preferences”, J Biol Chem., 281: 25678-88 (2006). [cited by applicant]
Derfus, et al., “Targeted Quantum Dot Conjugates for siRNA Delivery”, Bioconjug Chem, 18: 1391-6 (2007). [cited by applicant]
Derossi, et al., “Trojan peptides: the penetratin system for intracellular delivery”, Trends Cell Biol., 8:84-7 (1998). [cited by applicant]
Dharap, et al., “Targeted proapoptotic LHRH-BH3 peptide”, Pharm Res., 20:889-96 (2003). [cited by applicant]
Drake, et al., “Assessing tumor growth and distribution in a model of prostate cancer metastasis using bioluminescence imaging”, Clin Exp Metastasis, 22:674-684 (2005). [cited by applicant]
Duckert, et al., “Prediction of proprotein convertase cleavage sites”, Protein Eng. Design & Selection, 17(1):107-12 (2004). [cited by applicant]
Dykxhoorn, et al., “The silent treatment: siRNAs as small molecule drugs”, Gene Ther. 13:541-52 (2006). [cited by applicant]
Elango, et al., “The mumps virus fusion protein mRNA sequence and homology among the paramyxoviridae proteins”, J. Gen. Virol. 70:801-807 (1989). [cited by applicant]
Eliceiri and Cheresh, “Adhesion events in angiogenesis”, Curr Opin Cell Biol 13:563-68 (2001). [cited by applicant]
Elliott and O'Hare, “Intercellular trafficking and protein delivery by a herpesvirus structural protein”, Cell, 88:223-33 (1997). [cited by applicant]
Esmon, et al., “Cell mediated events that control blood coagulation and vascular injury”, Annu. Rev. Cell. Biol., 9:1-26 (1993). [cited by applicant]
Falanga, et al. “Wound bed score and its correlation with healing of chronic wounds”, Dermatol Ther 19:383-90 (2006). [cited by applicant]
Fenart and Cecchelli, “Protein transport in cerebral endothelium. In vitro transcytosis of transferring”, Meth. Mol. Med., 89:277-90 (2003). [cited by applicant]
Fogal, et al., “Mitochondrial/ Cell surface protein p32/gC1qR as a molecular target in tumor cells and tumor stroma”, Cancer Res., 68:7210-18 (2008). [cited by applicant]
Folkman, “Angiogenesis”, Annu Rev Med. 57:1-18, (2006). [cited by applicant]
Fujikawa, et al., “Activation of bovine factor X (Stuart factor): conversion of factor Xa alpha to factor Xa beta”, PNAS, 72:3359-63 (1975). [cited by applicant]
Gammon, et al., “Quantitative Analysis of Permeation Peptide Complexes Labeled with Technetium-99m: Chiral and Sequence-Specific Effects on Net Cell Uptake”, Bioconjugate Chem., 14:368-76 (2003). [cited by applicant]
GenBank Accession No. Q1YF93 “CueR-like heavy metal response, transcription regulator”, 1 page, Submitted Mar. 2006, first published May 2, 2006, accessed Aug. 24, 2011. [cited by applicant]
Geretti, et al., “Neuropilin structure governs VEGF and semaphorin binding and regulates angiogenesis”, Angiogenesis, 11:31-39 (2008). [cited by applicant]
Gonzalez-Reyes, et al., “Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion”, PNAS, 98:9859-64 (2001). [cited by applicant]
Goodman and Ro, “Peptidomimetics for Drug Design”, Buerger's Medicinal Chemistry Drug Discovery vol. 1 (ed M.E. Wolff; John Wiley & Sons, pp. 803-861 (1995). [cited by applicant]
Gordon, et al., “Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases”, Infec. Immun. 63:82-7(1995). [cited by applicant]
Grabitz, et al., “Science with no fiction: measuring the veracity of scientific reports by citation analysis”, 1-9, bioRxiv.org., Preprint Article (2017). [cited by applicant]
Grebrehiwet, et al., “gC1q-R/p33: structure-function predictions from the crystal structure”, Immunobiology, 205:421-32 (2002). [cited by applicant]
Green, et al., “Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein”, Cell, 55:1179-88 (1988). [cited by applicant]
Hagedorn and Bikfalvi, “Target molecules for anti-angiogenic therapy: from basic research to clinical trials”, Crit. Rev. Oncol. Hematol. 34:89-110 (2000). [cited by applicant]
Hambley and Hait,“Is Anticancer Drug Development Heading in the Right Direction?” Cancer Res., 69:1259-62 (2009). [cited by applicant]
Hamzah, et al., “Vascular Targeting of Anti-CD40/IL2 into Autochthonous Tumors Enhances Immunotherapy”, J. Clin. Invest., 118:1691-99 (2008). [cited by applicant]
Hanahan, “Heritable formation of pancreatic-cell tumors in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes”, Nature, 315:115-22 (1985). [cited by applicant]
Hann, “On the double bond isostere of the peptide bond: preparation of an enkephalin analogue”, J. Chem. Soc Perkin Trans., 1: 307-14 (1982). [cited by applicant]
Hansen, et al., “A urokinase-type plasminogen activator-inhibiting cyclic peptide with an unusuall P2 residue and an extended protease binding surface demonstrates new modalities for enzyme inhibition”, J Biol Chem., 28… [cited by applicant]
Heldin, et al., “High interstitial fluid pressure—an obstacle in cancer therapy”, Nat Rev Cancer 4:806-13 (2004). [cited by applicant]
Hezel, et al., “Genetics and biology of pancreatic ductal adenocarcinoma”, Genes Dev, 20:1218-49 (2006). [cited by applicant]
Hoffman, et al., “In vivo and ex vivo selections using phage-displayed libraries”, Phage Display: A Practical Approach, T. Clarkson and H. Lowman, eds. (Oxford, U.K.: Oxford University Press), Chap 10:171(2004). [cited by applicant]
Hoffman, et al., “Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma”, Cancer Cell, 4:383-91 (2003). [cited by applicant]
Holladay, et al., “Synthesis of hydroxyethylene and ketomethylene dipeptide isosteres”, Tetrahedron Lett, 24:4401-4 (1983). [cited by applicant]
Hong, et al., “Targeting neuropilin 1 as an antitumor strategy in lung cancer”, Clinical. Cancer Res., 13(6): 4759-68 (2007). [cited by applicant]
Hooper, et al., “Membrane protein secretases”, Biochem. J. 321:265-279 (1997). [cited by applicant]
Horswill, et al., “Cyclic Peptides, a Chemical Genetics Tool for Biologists”, Cell Cycle, 4(4):552-555 (2005). [cited by applicant]
Hruby, “Conformational restrictions of biologically active peptides via amino acid side chain groups”, Life Sci., 31:189-99 (1982). [cited by applicant]
Hudson, et al., “Methionine enkephalin and isosteric analogues. I. Synthesis on a phenolic resin support”. Int J Pept Prot Res., 14:177-85 (1979). [cited by applicant]
Ibba and Hennecke, “Towards engineering proteins by site-directed incorporation in vivo of non-natural amino acids”, Biotechnology, 12:678-82 (1994). [cited by applicant]
Ibba, “Strategies for in vitro and in vivo translation with non-natural amino acids”, Biotechnology and & Genetic Engineering Reviews, 13:197-216 (1995). [cited by applicant]
International Preliminary Report on Patentability and Written Opinion for PCT/US2009/031305 dated (Jul. 20, 2010). [cited by applicant]
International Search Report and Written Opinion for application PCT/US09/34713 dated Aug. 4, 2009. [cited by applicant]
International Search Report PCT application PCT/US2010/039539 dated Oct. 25, 2010. [cited by applicant]
International Search Report PCT/US2009/031305, mailed Mar. 10, 2010. [cited by applicant]
Jain, “Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy”, Science, 307:58-62 (2005). [cited by applicant]
Jain, “Vascular and interstitial barriers to delivery of therapeutic agents in tumors”, Cancer Metastasis Rev, 9:253-266 (1990). [cited by applicant]
Jain, et al., “Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model”, Cancer Res., 67:2729-35 (2007). [cited by applicant]
Jarvinen and Ruoslahti, “Molecular changes in the vasculature of injured tissues”, Am. J. Path., 171:702-711 (2007). [cited by applicant]
Jennings-White, et al., “Synthesis of ketomethylene analogs of dipeptides”, Tetrahedron Lett., 23:2533 (1982). [cited by applicant]
Jia, et al., “Characterization of a bicyclic peptide neuropilin-1 (NP-1) antagonist (EG3287) reveals importance of vascular endothelial growth factor exon 8 for NP-1 binding and role of NP-1 in KDR signaling”, J. Biol. … [cited by applicant]
Jia, et al., “Cysteine-rich and basic domain HIV-1 Tat peptides inhibit angiogenesis and induce endothelial cell apoptosis”, Biochem. Biophys. Res. Commun., 283:469-79 (2001). [cited by applicant]
Jiang, et al., Tumor imagining by means of proteolytic activation of cell-openetrating peptides, PNAS, 101:17867-72 (2004). [cited by applicant]
Johannsen, et al., “Proteins of purified Epstein-Barr virus”, PNAS, 101:16286-91 (2004). [cited by applicant]
Joliot, et al., “Antenapedia homeobox peptide regulates neural morphogenesis”, PNAS, 88:1864-68 (1991). [cited by applicant]
Joyce, et al., “Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis”, Cancer Cell, 4:393-403 (2003). [cited by applicant]
Kamei, et al., “Importance of intermolecular interaction on the improvement of intestinal therapeutic peptide/protein absorption using cell-penetrating peptides”, J Contr. Rel., 136:179-86 (2009). [cited by applicant]
Kamei, et al., “Usefulness of cell-penetrating peptides to improve intestinal insulin absorption.”, J Contr. Rel., 132:21-5 (2008). [cited by applicant]
Kandela, et al., “Registered report: Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs”, eLife. 10.7554/eLife.06959, includes opublished correction (2015). [cited by applicant]
Karmali, et al., “Targeting of albumin-embedded paclitaxel nanoparticles to tumors”, Nanomedicine, 5:73-82 (2009). [cited by applicant]
Ke, et al., “Optimal subsite occupancy and design of selective inhibitor of urokinase”, J. Biol. Chem., 272:20456-62 (1997). [cited by applicant]
Kerbel, et al., “The anti-angiogenic basis of metronomic chemotherapy”, Nat Rev Cancer, 4: 423-36 (2004). [cited by applicant]
Kirsch, et al., “Anti-angiogenic treatment strategies for malignant brain tumors”, J. Neurooncol., 50:149-63 (2000). [cited by applicant]
Klenk, et al., “Host cell proteases controlling virus pathogenicity”, Trends Microbiol, 2:39-43 (1994). [cited by applicant]
Koga, et al., “Nucleotide Sequence and Expression of the Feline Vascular Endothelial Growth Factor”, J. Vet. Med. Sci., 64(5):453-456 (2002). [cited by applicant]
Koivunen, et al., “Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins”, Biotechnology, 13:265-70 (1995). [cited by applicant]
Koivunen, et al., “Selection of peptides binding to the alpha 5 beta 1 integrin from phage display library”, J Biol Chem, 268:20205-10 (1993). [cited by applicant]
Kolonin, et al., “Synchronous selection of homing peptides for multiple tissues by in vivo phage display”, FASEB, 20:979-81 (2006). [cited by applicant]
Koya, et a., “Nucleotide sequence and expression of the feline vascular endothelial growth factor”, J Vet Med Sci., 64(5):453-6 (2002). [cited by applicant]
Kreitman and Pastan, “Recombinant toxins containing human granulocyte-macrophage colony-stimulating factor and either pseudomonas exotoxin or diphtheria toxin kill gastrointestinal cancer and leukemia cells”, Blood, 90:… [cited by applicant]
Kumar, et al., “Transvascular delivery of small interfering RNA to the central nervous system”, Nature, 448:39-43 (2007). [cited by applicant]
Laakkonen, et al., “A tumor-homing peptide with a targeting specificity related to lymphatic vessels”, Nature Med., 8:751-55 (2002b). [cited by applicant]
Laakkonen, et al., “Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells”, PNAS, 101:9381-86 (2004). [cited by applicant]
Laakkonen, et al., “Peptide targeting of tumor lymph vessels”, Ann NY Ac Sci., 1131:37-43 (2008). [cited by applicant]
Li and Huang “Surface-modified LPD nanoparticles for tumor targeting”, Ann N.Y. Acad. Sci. 1082, 1-8 (2006). [cited by applicant]
Li, et al., “The role of the transferrin-transferrin-receptor system in drug delivery and targeting”, Trends Pharmacol. Sci. 23, 206-209 (2002). [cited by applicant]
Liu, et al. “Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxim”, J Biol Chem. 276:17976-84 (2001). [cited by applicant]
Liu, et al., “In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice”, Nat. Nanotech., 2:47-52 (2007). [cited by applicant]
Liu, et al., “In vivo interrogation of the molecular display of atherosclerotic lesion surfaces”, American Journal of Pathology, 163:1859-71 (2003). [cited by applicant]
Liu, et al., “Prostate-specific Membrane Antigen Directed Selective Thrombotic Infarction of Tumors”, Cancer Res., 62:5470-5 (2002). [cited by applicant]
Maeda, et al., “Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications”, Int Immunopharmacol, 3:319-28 (2003). [cited by applicant]
Mantis, et al., “Replication Study: Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs”, eLife, 10.7554/eLife.17584 (2017). [cited by applicant]
Marin, et al., “Role of vascular nitric oxide physiological and pathological conditions”, Pharmacol Ther, 75:111-34 (1997). [cited by applicant]
Martin, et al., “Cancer gene therapy by thyroid hormone-mediated expression of toxin genes”, Cancer Res., 60:3218-24 (2000). [cited by applicant]
Mayer, et al., “The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors”, J Pharm. Exp Ther, 280:1406-14 (1997). [cited by applicant]
Meade and Dowdy, “Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides”, Adv. Drug Delivery Reviews. 59(2-3):134-40 (2007). [cited by applicant]
Medarova, et al., “In vivo imaging of siRNA delivery and silencing in tumors”,. Nat Med, 13: 372-7 (2007). [cited by applicant]
Miles and Miles, “Vascular reactions to histamine, histamine-liberator and leukotaxine in the skin of guinea-pigs”, J Physiol, 118:228-57 (1952). [cited by applicant]
Minchinton and Tannock, “Drug penetration in solid tumours”, Nat Rev Cancer 6:583-92 (2006). [cited by applicant]
Moghimi, et al., “Long-circulating and target-specific nanoparticles: Theory to practice”, Pharm. Rev. 53:283-318 (2001). [cited by applicant]
Morley, “Modulation of the action of regulatory peptides by structural modification”, Trends, Pharm Sci,. 463-468 (1980). [cited by applicant]
Moulard. and Decroly, “Maturation of HIV envelope glycoprotein precursors by cellular endoproteases”, Biochim. Biophys. Acta, 1469:121-132 (2000). [cited by applicant]
Murakami and Etlinger, “Degradation of proteins with blocked amino groups by cytoplasmic proteases”, Biochem. Biophys. Res. Comm., 146:1249-59 (1987). [cited by applicant]
Murohara, et al., “Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin”, Circ., 97:99-107 (1998). [cited by applicant]
Murphy, et al., “Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis”, PNAS, 105:9343-48 (2008). [cited by applicant]
Myrberg, et al., “Design of a Tumor-Homing Cell-Penetrating Peptide”, Bioconjugate Chem., 19:70-75 (2008). [cited by applicant]
Nyberg, et al., “Trypsins and their role in carcinoma growth”, Exp Cell Res., 312:1219-28 (2006). [cited by applicant]
Osborne and Coronado-Heisohn, “Targeting the epidermal growth factor receptor in breast cancer cell lines with a recombinant ligand fusion toxin (DAB389EGF)”, Cancer J. Sci. Am. 2:175 (1996). [cited by applicant]
Park, et al., “Magnetic iron oxide nanoworms for tumor targeting and imaging”,. Adv. Mater., 20:1630-5 (2008). [cited by applicant]
Park, et al., “Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting”, Small, 5:694-700 (2009). [cited by applicant]
Pasqualini, et al., “Alpha v integrins as receptors for tumor targeting by circulating ligands”, Nature Biotechnol., 15:542-6 (1997). [cited by applicant]
Pellet-Many, et al., “Neuropilins: structure, function and role in disease”, Biochem J, 411:211-26 (2008). [cited by applicant]
Pellinen, et al., “Integrin traffic”, J Cell Sci 119:3723-31 (2006). [cited by applicant]
Pero, et al., “Combination treatment with Grb7 peptide and Doxorubicin or Trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cells”, British Journal of Cancer, 96(10):1520-1525 (2007). [cited by applicant]
Pierschbacher and Ruoslatli, “Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule”, Nature, 309:30-33 (1984). [cited by applicant]
Pilch, et al., “Peptides selected for binding to clotted plasma accumulate in tumor stroma and wonds”, PNAS, 103:2800-4 (2006). [cited by applicant]
Pipkorn, et al. , “Delivery of substances and their target-specific topical activation”, Biochim Biophys Acta, 1758(5):606-10 (2006). [cited by applicant]
Pirollo, et al., “Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system”, Cancer Res., 67:2938-43 (2007). [cited by applicant]
Polyakov, et al., “Novel Tat-Peptide Chelates for Direct Transduction of Technetium-99m and Rhenium into Human Cells for Imaging and Radiotherapy”. Bioconjugate Chem., 11:762-71 (2000). [cited by applicant]
Porkka, et al., “A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo”, PNAS, 99:7444-9 (2002). [cited by applicant]
Puente, et al., “Human and mouse proteases: a comparative genomic approach”, Nat Rev Genet, 4:544-8 (2003). [cited by applicant]
Rajotte and Ruoshahti, “Membrane dipeptidase is the receptor for a lung-targeting peptide identified by in vivo phage display”, J. Biol. Chem., 274:11593-11598 (1999). [cited by applicant]
Rajotte, et al., “Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display”, J Clin Invest., 102:430-7 (1998). [cited by applicant]
Rijken, “Plasminogen activators and plasminogen activator inhibitors: biochemical aspects”, Baillieres Clin Haematol., 8:291-312 (1995). [cited by applicant]
Rizo and Gierasch, “Constrained peptides: models of bioactive peptides and protein substructures”, Ann. Rev. Biochem., 61:387 (1992). [cited by applicant]
Rubinstein, et al., “Receptor for the globular heads of C1q (gC1q-R, p33, hyaluronan-binding protein) is preferentially expressed by adenocarcinoma cells”, Int J Cancer 100:741-50 (2004). [cited by applicant]
Ruiz-Linares, et al., “Processing of yellow fever virus polyprotein: role of cellular proteases in maturation of the structural proteins”, J. Virol., 63:4199-4209 (1989). [cited by applicant]
Ruoslahti and Rajotte, “An address system in the vasculature of normal tissues and tumors”, Annu. Rev. Immunol., 18:813-827 (2000). [cited by applicant]
Ruoslahti, “RGD story: a personal account. A Landmark Essay”, Matrix Biology 2:459-65 (2003). [cited by applicant]
Ruoslahti, “Specialization of tumour vasculature”, Nat. Rev. Cancer, 2:83-90 (2002). [cited by applicant]
Ruoslahti, et al., “Targeting of drugs and nanoparticles to tumors”, The Journal of Cell Biology, 188(6):759-768 (2010). [cited by applicant]
Ruoslahti,. “Drug targeting to specific vascular sites”, Drug Discovery Today. 7:1138-43 (2002). [cited by applicant]
Ruoslahti, “Vascular zip codes in angiogenesis and metastasis”, Biochem. Soc. Transact., 32:397-402 (2004). [cited by applicant]
Rusnak, et al., “The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo”, Mol Canc… [cited by applicant]
Sanchez, et al., “Crimean-congo hemorrhagic fever virus glycoprotein precursor is cleaved by Furin-like and SKI-1 proteases to generate a novel 38-kilodalton glycoprotein”, J. Virol., 80:514-25 (2006). [cited by applicant]
Sandgren, et al., “Nuclear targeting of macromolecular polyanious by an HIV—Tate derived peptide. Role for cell-surface proteoglycans”, J. Biol. Chem., 277:38877-83 (2002). [cited by applicant]
Sehgal, et al., “Photoinduced cytotoxicity and biodistribution of prostate cancer cell-targeted porphyrins”, J. Med. Chem, 51:6014-20 (2008). [cited by applicant]
Simberg, et al., “Biomimetic amplification of nanoparticle homing to tumors”, PNAS, 104:932-936 (2007). [cited by applicant]
Singer, et al., “Cutaneous wound healing”, NEJM, 341:738-46 (1999). [cited by applicant]
Sipkins, et al., “Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging”, Nat. Med., 4:623-26 (1998). [cited by applicant]
Sjoberg, et al., “Furin cleavage potentiates the membrane fusion-controlling intersubunit disulfide bond isomerization activity of leukemia virus”, Env. J. Virol., 80:5540-51 (2006). [cited by applicant]
Smyth and Trapani, “Granzymes: exogenous proteinases that induce target cell apoptosis”, Immunology Today, 16: 202-206 (1995). [cited by applicant]
Soker, et al., “Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor”, Cell, 92:735-45 (1998). [cited by applicant]
Sokoloff, et al., “A new peptide ligand that targets particles and heterologous proteins to hepatocyctes in vivo”, Mol. Ther. 8:867-72 (2003). [cited by applicant]
Sokoloff, et al., “The interactions of peptides with the innate immune system studied with use of T7 phage peptide display”, Mol. Ther., 2:131-39 (2000). [cited by applicant]
Spatola, et al., “Structure-activity relationships of enkephalins containing serially replaced thiomethylene amide bond surrogates”, Life Sci 38:1243-9 (1986). [cited by applicant]
Spatola, “Peptide Backbone Modifications”, Chemistry and Biochemistry of Amino Acids, Pepides, and Proteins, B. Weinstein, eds., Marcel Dekker, New York, p. 267 (1983). [cited by applicant]
Spiridon, et al., “Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo”, Clin Cancer Res, 8:1720-30 (2002). [cited by applicant]
Starzec, et al., “Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1”, Life Sci, 79:2370-81 (2006). [cited by applicant]
Steinhauer, “Role of hemagglutinin cleavage for the pathogenicity of influenza virus”, Virology, 258:1-20 (1999). [cited by applicant]
Sternlicht, et al., “How matrix metalloproteinases regulate cell behavior”, Annu. Rev. Cell. Dev. Biol., 17:463-513 (2001). [cited by applicant]
Sugahara, et al. “Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs”, Am. Assoc. Adv of Sci., 328(5981): 1031-35 (2010). [cited by applicant]
Sugahara, et al., “Chondroitin sulfate E fragments enhance CD44 cleavage and CD44 dependent motility in tumor cells”, Cancer Res., 68:7191-9 (2008). [cited by applicant]
Sugahara, et al., “Hyaluronan oligosaccharides induce CD44 cleavage and promote cell migration in CD44-expressing tumor cells”, J Biol Chem., 278:32259-65 (2003). [cited by applicant]
Sugahara, et al., “Tissue penetrating delivery of compounds and nanoparticles into tumors”, Cancer Cell 16(6):510-20 (2009). [cited by applicant]
Talanian, et al., “Substrate specificities of caspase family proteases”, J. Biol. Chem., 272: 9677-82 (1997). [cited by applicant]
Teesalu, et al., “Tumor-Penetrating Peptides”, Frontiers in Oncology, 3(216): 1-8 (2013). [cited by applicant]
Teesalu, et al., “C-end rule peptides mediate neuropilin-1-dependent cell, vascular and tissue penetration”, PNAS, 106(38):16157-62 (2009). [cited by applicant]
Thomas, “Furin at the cutting edge: from protein traffic to embryogenesis and disease”, Nature Rev. Mol. Cell. Biol. 3:753-66 (2002). [cited by applicant]
Thomas, et al., “Tissue distribution and pharmacokinetics of an ATWLPPR-conjugated chlorin-type photosensitizer targeting neuropilin-1 in glioma-bearing nude mice”, Photochemical & photobiological Sciences, 7(4):433 (20… [cited by applicant]
Thornberry, et al., “A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis”, J. Biol. Chem. 272: 17907-11 (19… [cited by applicant]
Thorson, et al., “A biosynthetic approach for the incorporation of unnatural amino acids into proteins”, Methods in Molec. Biol., 77:43-73 (1991). [cited by applicant]
Thurber, et al., “Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance”, Adv Drug Deliv Rev, 60:1421-34 (2008). [cited by applicant]
Tian, et al., “A 20 residues Motif Delineates the Furin Cleavage Site and its Physical Properties May Influence Viral Fusion”, BioChemistry Insights, 2:9-20 (2009). [cited by applicant]
Tirand, et al., “A peptide competing with VEGF165 binding on neuropilin-1 mediates targeting of a chlorin-type photosensitizer and potentiates its photodynamic activity in human endothelial cells”, J Contr. Rel., 111:15… [cited by applicant]
Tkachenko, et al., “Multifunctional gold nanoparticle-peptide complexes for nuclear targeting”, J Am Chem Soc. 125:4700-1 (2003). [cited by applicant]
Torgersen, et al., “Internalization of cholera toxin by diffeent endocytic mechanisms”, J. Cell. Sci., 114:3737-47 (2001). [cited by applicant]
Tucker, “Alpha v integrin inhibitors and cancer therapy”, Curr Opin Investig Drugs 4:722-31 (2003). [cited by applicant]
Tyagi, et al., “Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans”, J. Biol. Chem., 276:3254-61 (2001). [cited by applicant]
Uhland, “Matriptase and its putative role in cancer”, Cell. Mol. Life Sci., 63:2968-78 (2006). [cited by applicant]
Uprichard, “The therapeutic potential of RNA interference”, FEBS Lett., 579:5996-6007 (2005). [cited by applicant]
Vander Kooi, et al., “Structural basis for ligand and heparin binding to neuropilin B domains”, PNAS, 104(15):6152-57 (2007). [cited by applicant]
Varsanyi, et al., “Isolation and characterization of the measles virus F1 polypeptide: comparison with other paramyxovirus fusion proteins”, Virology 147:110-17 (1985). [cited by applicant]
Vey, et al., “Proteolytic processing of human cytomegalovirus glycoprotein B (gpUL55) is mediated by the human endoprotease furin”, Virology 206:746-49 (1995). [cited by applicant]
von Maltzahn, et al., “In vivo tumor cell targeting with “click” nanoparticles”, Bioconjug Chem, 19:1570-8 (2008). [cited by applicant]
Weissleder, et al., “Cell-specific targeting of nanoparticles by multivalent attachment of small molecules”, Nat. Biotechnol., 23:1418-23 (2005). [cited by applicant]
Weissleder, et al., “Long-circulating iron oxide for MR imaging”, Adv. Drug Deliv. Rev., 16: 321-34 (1995). [cited by applicant]
Werb, “ECM and cell surface proteolysis: regulating cellular ecology”, Cell, 91:439-42 (1997). [cited by applicant]
White, et al. Antibody-targeted immunotherapy for treatment of malignancy, Annu Rev Med., 52:125-41 (2001). [cited by applicant]
Wolfsberg, et al., “ADAM, a novel family of membrane proteins containing A Disintegrin and Metalloprotease domain: multipotential functions in cell-cell and cell-matrix interactions”, J. Cell Biol., 131:275-8 (1995). [cited by applicant]
Wool-Lewis and Bates, “Endoproteolytic processing of the ebola virus envelope glycoprotein: cleavage is not required for function”, J. Virol. 73:1419-26 (1999). [cited by applicant]
Yang, et al., “A fluorescent orthotopic bone metasis model of human prostate cancer”, Cancer Res, 59:781-6, 1999). [cited by applicant]
Yuan, et al., “Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft”, Cancer Res, 54:3352-56 (1994). [cited by applicant]
Zhang, et al., “Dynamic imaging of arginine-rich heart-targeted vehicles in a mouse model”, Biomaterials, 29:1976-88 (2008). [cited by applicant]
Zhang, et al., Lymphatic zip codes in premalignant lesions and tumors. Cancer Res. 66, 5696-5706 (2006). [cited by applicant]
Zhang, et al., “Molecular profiling of heart endothelial cells”, Circulation. 112:1601-11 (2005). [cited by applicant]
Zorko and Langel, “Cell-penetrating peptides: mechanism and kinetics of cargo delivery”, Adv Drug Deliv Rev. 57:529-45 (2005). [cited by applicant]